{"id":"W4409821756","doi":"10.1158/1538-7445.am2025-ct205","title":"Abstract CT205: Updated clinical results, recommended phase 2 dose (RP2D) determination and translational study results for START-001: A phase 1/2 trial of invikafusp alfa, a first-in-class TCR b chain-targeted bispecific antibody in patients with anti-PD(L)1-resistant, antigen-rich solid tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Oncology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01056164,0.001376951,0.001805638,0.001356011,0.0008336858,0.00301239,0.002426703,0.002376605,0.01109794],"category_scores_gemma":[0.007034881,0.0006946,0.001451293,0.001876723,0.0005879161,0.001327116,0.000726265,0.004605321,0.004877236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00317583,"about_ca_system_score_gemma":0.005697305,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002546682,"about_ca_topic_score_gemma":0.005756706,"domain_scores_codex":[0.9960231,0.001822489,0.0003348252,0.0002657145,0.001215687,0.0003381935],"domain_scores_gemma":[0.9915395,0.001568966,0.001689324,0.0008548748,0.002403815,0.001943416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1261556,0.005281113,0.01660347,0.003126607,0.001876658,0.0009698406,0.0003454023,0.005450024,0.0726678,0.002028055,0.3975308,0.3679647],"study_design_scores_gemma":[0.1017452,0.1132594,0.100086,0.0008794299,0.003127548,0.004307562,0.0001744669,0.004067682,0.05375762,0.001832436,0.6164463,0.0003162571],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.3778249,0.03739072,0.03098505,0.02961894,0.005258722,0.02471165,0.3444594,0.00667329,0.1430774],"genre_scores_gemma":[0.4711393,0.009794218,0.05362593,0.02044951,0.002239017,0.01278135,0.3891353,0.001639345,0.03919598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01109794,"threshold_uncertainty_score":0.05585599,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1021588390068308,"score_gpt":0.4807357307747102,"score_spread":0.3785768917678794,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}